NASDAQ: ACETAdicet Bio Inc Stock Ownership - Who owns Adicet Bio?
Insider buying vs selling
Have Adicet Bio Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Blake Aftab | Chief Scientific Officer | 2026-01-24 | 535 | $8.44 | $4.52kSell |
| Brian Nicholas Harvey | Chief Financial Officer | 2026-01-24 | 546 | $8.44 | $4.61kSell |
| Don Healey | Chief Technology Officer | 2026-01-24 | 535 | $8.44 | $4.52kSell |
| Chen Schor | President CEO | 2026-01-24 | 1,755 | $8.44 | $14.81kSell |
| Orbimed Advisors LLC | 10% Owner | 2025-10-08 | 1,500,000 | $1.00 | $1.50MBuy |
| Orbimed Advisors LLC | 10% Owner | 2025-10-08 | 3,500,000 | $1.00 | $3.50MBuy |
ACET insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when ACET insiders and whales buy or sell their stock.
ACET Shareholders
What type of owners hold Adicet Bio Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Orbimed Advisors LLC | 119.51% | 11,447,140 | $97.76M | Institution |
| Tang Capital Management LLC | 85.86% | 8,223,612 | $70.23M | Institution |
| Ra Capital Management LP | 78.73% | 7,541,000 | $64.40M | Institution |
| Jonathan Silverstein | 50.43% | 4,830,387 | $41.25M | Insider |
| Goldman Sachs Group Inc | 39.17% | 3,751,617 | $32.04M | Institution |
| Vanguard Group Inc | 34.17% | 3,272,522 | $27.95M | Institution |
| Carlyle Group Inc | 30.78% | 2,948,718 | $25.18M | Institution |
| Acadian Asset Management LLC | 23.65% | 2,265,491 | $19.35M | Institution |
| Andrew Sinclair | 22.27% | 2,133,085 | $18.22M | Insider |
| Puretech Health LLC | 22.13% | 2,119,696 | $18.10M | Insider |
ACET vs Biotech Stocks
Adicet Bio Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.